Abstract:Identifying mRNA (gene) and microRNA (miRNA) regulated in Duchenne muscular dystrophy (DMD) may aid in identifying prognostic biomarkers and developing novel treatments. Thus we performed genome-wide transcriptome profiling of whole blood and identified mRNAs and miRNAs regulated in DMD and following steroid treatment. The data show many regulated mRNAs and some miRNAs, including some muscle-specific miRNAs (e.g., miR-206, miR-133a) that were significantly altered in the blood of young (age 3–10) DMD patients compared to young controls. A total of 95 miRNAs but no mRNAs were differentially expressed in older DMD patients compared to older controls (age 11–20). Steroid treatment reversed the expression patterns of several miRNAs (miR-206, miR-181a, miR-4538, miR-4539, miR-606, and miR-454) that were altered in the young DMD patients. As an example, the over-expression of miR-206 in young DMD patients is predicted to down-regulate a set of target genes (e.g., RHGAP31, KHSRP, CORO1B, PTBP1, C7orf58, DLG4, and KLF4) that would worsen motor function. Since steroids decreased miR-206 expression to control levels, this could provide one mechanism by which steroids improve motor function. In addition, steroid treatment also decreased miR-4539 expression that would result in upregulation of target genes that affect glycogen metabolism and glucose transport which could improve the skeletal muscle, pulmonary and cardiac function. The identified miRNA–mRNA networks will help understand the pathophysiology of DMD and the response to steroid treatment.

microRNA and mRNA expression networks in Duchenne muscular dystrophy